KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Accumulated Expenses (2017 - 2025)

Moderna (MRNA) has disclosed Accumulated Expenses for 7 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 2.87% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a 2.87% decrease, with the full-year FY2025 number at $1.4 billion, down 2.87% from a year prior.
  • Accumulated Expenses was $1.4 billion for Q4 2025 at Moderna, up from $1.0 billion in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $2.1 billion in Q4 2022 to a low of $1.0 billion in Q1 2025.
  • A 5-year average of $1.5 billion and a median of $1.5 billion in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: soared 213.19% in 2021, then fell 20.63% in 2024.
  • Moderna's Accumulated Expenses stood at $1.5 billion in 2021, then soared by 42.73% to $2.1 billion in 2022, then dropped by 14.42% to $1.8 billion in 2023, then dropped by 20.63% to $1.4 billion in 2024, then decreased by 2.87% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Accumulated Expenses are $1.4 billion (Q4 2025), $1.0 billion (Q1 2025), and $1.4 billion (Q4 2024).